First hospital in Midwest to offer patients IntelliSep ® , an eight-minute blood test for sepsis detection SAN FRANCISCO and MILWAUKEE , Aug. 21, 2024 /PRNewswire/ -- Cytovale ® , a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced that the Froedtert & the Medical College of Wisconsin health network is now screening patients with IntelliSep ® in a pilot at its flagship hospital, Froedtert Hospital in Milwaukee . IntelliSep is the first U.
S. Food and Drug Administration (FDA)-cleared rapid diagnostic test for the early detection of sepsis in an emergency department (ED) setting. Froedtert Hospital is the first in Wisconsin and in the Midwest to offer this life-saving technology.
Sepsis is the leading cause of death in U.S. hospitals, with more than one-third of all in-hospital deaths attributed to the condition.
About 80% of sepsis patients present to emergency departments, where it can be difficult to discern from ordinary infections or other conditions that can mimic sepsis. "The Froedtert & MCW health network is committed to offering patients the best care and a definitive test is a valuable addition to our sepsis management program. A team of Medical College of Wisconsin researchers has worked closely with Cytovale over the years.
We see the potential impact a sepsis test can have on improving patient care and streamlining efficiencies in hospital operation.